NM_000742.4(CHRNA2):c.1105del (p.Ala369fs) AND Autosomal dominant nocturnal frontal lobe epilepsy

Germline classification:: Uncertain significance (1 submission)
Last evaluated:: Dec 13, 2020
Review status:: 1 star out of maximum of 4 stars
criteria provided, single submitter

Somatic classification of clinical impact:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Somatic classification of oncogenicity:: None
Review status:: (0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided

Record status:: current
Accession:: RCV001957476.4

Allele description [Variation Report for NM_000742.4(CHRNA2):c.1105del (p.Ala369fs)]

NM_000742.4(CHRNA2):c.1105del (p.Ala369fs)

Gene:

CHRNA2:cholinergic receptor nicotinic alpha 2 subunit [Gene - OMIM - HGNC]

Variant type:

Deletion

Cytogenetic location:

8p21.2

Genomic location:

Preferred name:

NM_000742.4(CHRNA2):c.1105del (p.Ala369fs)

HGVS:

NC_000008.11:g.27463343del
NG_015827.1:g.20959del
NM_000742.4:c.1105delMANE SELECT
NM_001282455.2:c.1060del
NM_001347705.2:c.628del
NM_001347706.2:c.628del
NM_001347707.2:c.511del
NM_001347708.2:c.511del
NP_000733.2:p.Ala369fs
NP_001269384.1:p.Ala354fs
NP_001334634.1:p.Ala210fs
NP_001334635.1:p.Ala210fs
NP_001334636.1:p.Ala171fs
NP_001334637.1:p.Ala171fs
NC_000008.10:g.27320855del
NC_000008.10:g.27320860del

Protein change:

A171fs

Links:

dbSNP: rs757376257

NCBI 1000 Genomes Browser:

rs757376257

Molecular consequence:

NM_000742.4:c.1105del - frameshift variant - [Sequence Ontology: SO:0001589]
NM_001282455.2:c.1060del - frameshift variant - [Sequence Ontology: SO:0001589]
NM_001347705.2:c.628del - frameshift variant - [Sequence Ontology: SO:0001589]
NM_001347706.2:c.628del - frameshift variant - [Sequence Ontology: SO:0001589]
NM_001347707.2:c.511del - frameshift variant - [Sequence Ontology: SO:0001589]
NM_001347708.2:c.511del - frameshift variant - [Sequence Ontology: SO:0001589]

Condition(s)

Name:: Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE)
Identifiers:: MONDO: MONDO:0020300; MedGen: C3696898

Recent activity

Clear Turn Off Turn On

Chain W, Proteasome subunit beta type-3
Chain W, Proteasome subunit beta type-3
gi|2324451243|pdb|7NAN|W

Protein

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Help

Submission Accession	Submitter	Review Status (Assertion method)	Clinical Significance (Last evaluated)	Origin	Method	Citations
SCV002202603	Labcorp Genetics (formerly Invitae), Labcorp	criteria provided, single submitter (Invitae Variant Classification Sherloc (09022015))	Uncertain significance (Dec 13, 2020)	germline	clinical testing	PubMed (1) [See all records that cite this PMID]

Submission Accession

Submitter

Review Status
(Assertion method)

Clinical Significance
(Last evaluated)

Origin

Method

Citations

SCV002202603

Labcorp Genetics (formerly Invitae), Labcorp

criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))

Uncertain significance
(Dec 13, 2020)

germline

clinical testing

PubMed (1)
[See all records that cite this PMID]

Help

Summary from all submissions

Ethnicity	Origin	Affected	Individuals	Families	Chromosomes tested	Number Tested	Family history	Method
not provided	germline	unknown	not provided	not provided	not provided	not provided	not provided	clinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240. doi: 10.1038/s41436-019-0624-9.

PubMed [citation]

PMID:: 28492532
PMCID:: PMC5632818

Details of each submission

From Labcorp Genetics (formerly Invitae), Labcorp, SCV002202603.3

#	Ethnicity	Individuals	Chromosomes Tested	Family History	Method	Citations
1	not provided	not provided	not provided	not provided	clinical testing	PubMed (1)

Description

This sequence change creates a premature translational stop signal (p.Ala369Profs*11) in the CHRNA2 gene. It is expected to result in an absent or disrupted protein product. However, the current clinical and genetic evidence is not sufficient to establish whether loss-of-function variants in CHRNA2 cause disease. This variant is not present in population databases (ExAC no frequency). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with CHRNA2-related conditions.

#	Sample				Method		Observation
#	Origin	Affected	Number tested	Tissue	Purpose	Method	Individuals	Allele frequency	Families	Co-occurrences
1	germline	unknown	not provided	not provided	not provided		not provided	not provided	not provided	not provided

Last Updated: Sep 29, 2024

ClinVar

Relating variation to medicine